BioSpace News Archive

rBIO launched last week with technology that can reduce the cost of insulin by 30 percent, making U.S. manufacturing cost-effective for insulin and several other drugs.

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

Presidio Bay Ventures partnered with Kinship Capital to acquire a piece of property in the Northern California city to redevelop into a space for the life sciences industry.

The U.S. Department of Defense awarded Moderna a contract worth $1,966,598,000 for an additional 100 million doses of its COVID-19 vaccine.

Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC), today announced CEO, Chairman and Founder, Calvin H. Knowlton, Ph.D.; Co-Founder, President, Chief Marketing and Business Development Officer, Orsula V. Knowlton, PharmD; Chief Sales Officer, Kevin Boesen; and Chief Financial Officer, Brian W. Adams, will participate in the 39 th Annual J.P. Morgan Healthcare Conference to be held virtually January 11-14, 2021. The TRHC presentation is schedule

BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that CEO Dr. Lan Huang is scheduled to present virtually at the 39 th Annual J.P. Morgan Healthcare Conference (JPM) on Thursday, January 14, 2021 at 7:30 a.m. ET, and will be available for 1x1 meetings. The BeyondSpring leadership team also will be available for one-on-one meeti

- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that Judge William C. Bryson of the United States District Court of Delaware has postponed the February 8, 2021 jury trial scheduled to hear arguments in the patent litigation case of Lipo

Medifast, Inc . (NYSE: MED), the global company behind one of the fastest-growing health and wellness communities, OPTAVIA®, announced today that Dan Chard , Chairman and Chief Executive Officer, and Jim Maloney , Chief Financial Officer, will present at the 23rd Annual ICR Conference on Monday, January 11, 2021 virtually.

Initiation of Phase 1/2 clinical study of novel peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein (FAP) expected 1H 2021 Will be the first peptide-targeted radionuclide therapy targeting FAP to enter clinical development

Moderna to Present at the Goldman Sachs 13 th Annual Healthcare CEOs Unscripted Conference: A View from the Top